ArticleInternational journal of clinical and experimental pathology2017
SATB2 induces stem-like properties and promotes epithelial-mesenchymal transition in hepatocellular carcinoma.
Article in International journal of clinical and experimental pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 4 citations in OpenAlex.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is one of the most prevailing malignancies, and the molecular mechanisms underlying HCC tumorigenesis remain to be further clarified. The aim of our present study was to determine the biological functions and clinical significance of SATB2 in HCC. Quantitative RT-PCR was performed to detect SATB2 mRNA expression in HCC tissues and cells. Cell proliferation, migration and invasion were investigated by MTT assay and transwell assay. Western blotting was performed to evaluate the protein expression levels. Tumor xenografts were established to explore the effects of SATB2 on HCC tumor growth in vivo. Our results indicated that SATB2 was highly expressed in HCC tissues and cell lines, and its high expression was closely correlated with aggressive clinical phenotypes and poor prognosis of HCC patients. Through gain- and loss-of function experiments, we found that SATB2 significantly promoted HCC cell proliferation, migration, and invasion in vitro and HCC tumorigenicity in vivo. Furthermore, SATB2 was identified as an important regulator of stem-like properties and epithelial to mesenchymal transition (EMT) in HCC cells. In summary, our results suggested that SATB2 is a crucial upregulator of HCC, and SATB2 might be a potential prognostic marker and a therapeutic target for HCC.
Indexed as
Identifiers
31966558PMC6966065W3027314268What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.